Home › Targets › MS4A1
Radioligand therapy target profile

CD20 (MS4A1): IHC Expression in Cancer and Radioligand Target Profile

membrane spanning 4-domains A1 · Ensembl ENSG00000156738 · Data updated 2026-11-01
Also known as: MS4A1

CD20 (MS4A1), membrane spanning 4-domains A1, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, CD20 staining is highest in lymphoma (100% of samples positive) and lung cancer (8% of samples positive). Evidence on whether CD20 internalizes is mixed. Clinical status: FDA-approved drug (any modality).

Is CD20 the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.

Analyze CD20 free
LocalizationCell-Surface
Top cancer (IHC)Lymphoma
InternalizationUncertain
Clinical stageFDA-approved drug (any modality)
Active trialsSee ClinicalTrials.gov
Cancer association (Open Targets)0.64

Is CD20 a good radioligand therapy target?

Scored against the six criteria that decide whether a protein can become a radioligand therapy:

CD20 IHC staining by cancer type

Protein expression of CD20 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.

Cancer typeIHC scoreLevel% positive
Lymphoma0.97High100%
Lung Cancer0.03Low8%

Not detected by IHC in: skin cancer, colorectal cancer, head and neck cancer, ovarian cancer, breast cancer, melanoma, kidney cancer, thyroid cancer, bladder cancer, neuroendocrine tumors, cervical cancer, pancreatic cancer, prostate cancer, gastric cancer, testicular cancer, endometrial cancer, glioma, liver cancer.

Is CD20 internalized?

Uncertain. Insufficient literature found.

CD20 clinical trials

FDA-approved drug (any modality). Nuclens hasn't indexed trials for CD20 yet. Search ClinicalTrials.gov for CD20 trials.

CD20 normal tissue expression

Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See CD20 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.

CD20 gene essentiality (DepMap)

CRISPR knockout effect across 1241 cancer cell lines: 0.13 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.

Related lymphoma radioligand targets

c-MET (MET) · HER3 (ERBB3) · CD19 · CD45 (PTPRC) · SSTR2 · CD22 · STEAP2 · TMEFF2

See all radioligand therapy targets in lymphoma.

See how CD20 ranks against 15,000 targets for your indication.

Analyze CD20 free

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Is CD20 the right target for your program? · 5 free analyses, no card Analyze CD20 free